Targeted nanoparticles containing monoseleno-linked polycurcuminoids, methods of making and uses thereof
Patent Information
- Application Number
- CN202611404138.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-10
- Publication Date
- 2026-11-03
AI Technical Summary
现有姜黄素药物在治疗神经认知功能障碍时面临递送效率低下,传统纳米药物递送系统缺乏智能响应性和主动靶向性,氧化应激与神经炎症恶性循环难以协同干预。
We constructed targeted nanoparticles containing monoselenomeric curcumin and combined them with Tet-1 peptide to achieve reactive oxygen species-responsive drug release and neuronal targeting. Through size effect, these nanoparticles target diseased tissues, cross the blood-brain barrier, and are precisely delivered to diseased neurons.
It increased the effective drug concentration of curcumin in brain lesions, achieved synergistic regulation of oxidative stress and neuroinflammation, significantly improved spatial learning and memory ability in mice, and protected hippocampal neuronal morphology.
Smart Images

Figure CN123024044A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to targeted nanoparticles containing monoselenide-bonded curcumin, their preparation methods, and applications. Background Technology
[0002] Neurocognitive impairment, including Alzheimer's disease and vascular dementia, is a major public health problem posing a serious threat to the health of older adults worldwide. Its pathological mechanisms are complex, involving multiple interrelated processes such as oxidative stress, neuroinflammation, protein misfolding and aggregation, neuronal loss, and synaptic dysfunction. Among these, oxidative stress and neuroinflammation are considered the two core pathological processes driving disease development; they mutually promote each other, forming a vicious cycle that ultimately leads to neuronal damage and cognitive decline. Drugs using a single mechanism often have limited efficacy; therefore, developing therapeutic strategies that can simultaneously and synergistically regulate oxidative stress and inflammatory responses is crucial for effectively intervening in neurocognitive impairment.
[0003] In the current field of drug therapy, curcumin, a natural polyphenolic compound extracted from the rhizome of turmeric, has attracted much attention due to its remarkable multiple pharmacological activities, including antioxidant, anti-inflammatory, anti-amyloid aggregation, and neuroprotective effects. Numerous preclinical studies have shown that curcumin can demonstrate good therapeutic effects in various neurodegenerative disease models through multiple mechanisms, such as scavenging reactive oxygen species, inhibiting inflammatory signaling pathways like nuclear factor κB, and regulating mitochondrial function. However, the physicochemical properties of curcumin itself severely limit its clinical application. First, curcumin has extremely poor water solubility, resulting in very low oral bioavailability. Second, it has poor chemical stability under physiological conditions and is prone to photolysis and degradation. Most importantly, curcumin has difficulty effectively penetrating the blood-brain barrier, a natural physiological barrier protecting the central nervous system, resulting in effective drug concentrations reaching the brain parenchyma far below the levels required for treatment. Although researchers have tried various dosage form improvement strategies, such as liposomes, micelles, and solid dispersions, these traditional delivery systems often lack the ability to actively target the diseased brain regions and cannot respond to abnormally elevated pathological microenvironments in the brain (such as high levels of reactive oxygen species), resulting in limited drug accumulation efficiency at the lesion site and the potential for unnecessary systemic side effects.
[0004] Nanotechnology offers new insights into overcoming these challenges. Intelligent nanodelivery systems can passively target diseased tissues through size effects and achieve cell-specific recognition through active targeting ligands via surface modification. More importantly, by introducing chemical bonds that respond to specific pathological stimuli, "intelligent" drug release systems can be constructed, enabling on-demand and controllable drug release at the lesion site. In the field of neurological diseases, reactive oxygen species (ROS)-responsive nanocarriers have been extensively studied due to their specific response to pathologically elevated ROS levels in the brain. Common ROS-responsive bonds include thioketals, borate esters, and selenium bonds. Among these, selenium-containing compounds exhibit unique advantages due to their higher ROS-responsive sensitivity compared to sulfur-containing analogs. Single selenium bonds can break under physiological levels of ROS stimulation, thereby achieving rapid drug release. However, how to efficiently and stably integrate ROS responsiveness, natural therapeutic drugs, and brain-targeting functions to construct a multifunctional synergistic nanoplatform remains a key technological bottleneck in this field. Many existing nanosystems have relatively singular functions or suffer from problems such as complex synthesis, poor biocompatibility, poor in vivo stability, and low targeting efficiency.
[0005] Furthermore, secondary targeting beyond the blood-brain barrier is crucial for efficient drug delivery to neurons. Tet-1 peptide, a 12-amino acid short peptide derived from tetanus toxin, has been shown to mediate efficient internalization of the carrier into neurons by binding to specific receptors on the neuronal surface, thereby achieving active targeting of neurons. Combining Tet-1 peptide with reactive oxygen species-responsive nanocarriers holds promise for constructing a three-tiered delivery system of "barrier crossing-neuron recognition-response release," significantly improving drug accumulation and therapeutic efficiency within diseased neurons. Currently, there are no reports on the integrated design and construction of polymers containing single selenium bonds, the natural drug curcumin, and the neuronal-targeting peptide Tet-1, and a systematic evaluation of their comprehensive therapeutic efficacy for neurocognitive dysfunction. Therefore, developing a novel nanodelivery system integrating intelligent response, efficient targeting, and multiple therapeutic functions has an urgent theoretical need and broad clinical application prospects for advancing precision treatment of neurocognitive dysfunction. Summary of the Invention
[0006] The first objective of this invention is to address the technical problem of low delivery efficiency of existing curcumin drugs in the treatment of neurocognitive disorders; the second objective is to address the technical problem of the lack of intelligent responsiveness and active targeting in the treatment of neurological diseases using traditional nanomedicine delivery systems; and the third objective is to address the difficulty in synergistically intervening in the vicious cycle of oxidative stress and neuroinflammation in the pathological process of neurocognitive disorders. To solve the above problems, this invention constructs targeted nanoparticles containing monoselenopolymer curcumin and provides its preparation method and applications.
[0007] According to a first aspect of the present invention, targeted nanoparticles containing monoselenomeric curcumin are provided, the raw material mainly consisting of monoselenomeric curcumin and DSEP-PEG; The structural formula of curcumin containing a single selenium bond is: Formula (I), In equation (I), n is 2-100.
[0008] This invention utilizes monoselenomeric curcumin, which exhibits better chemical stability than curcumin alone, allowing it to penetrate the blood-brain barrier and reach brain lesions. The monoselenomeric curcumin, with its single selenium bond, rapidly releases curcumin within an oxidative stress microenvironment, endowing the nanoparticles with high responsiveness to pathological levels of reactive oxygen species (ROS). Based on monoselenomeric curcumin, this invention successfully constructs targeted nanoparticles integrating intelligent responsive release, efficient neuronal targeting, and multiple neuroprotective functions of curcumin. Utilizing size effects to target diseased tissue, these nanoparticles efficiently cross the blood-brain barrier and precisely deliver to diseased neurons. In vitro cell experiments have confirmed that these targeted nanoparticles effectively scavenge ROS within neurons, enhance superoxide dismutase activity, and reduce malondialdehyde levels, demonstrating superior antioxidant capacity compared to free curcumin and untargeted nanoparticles. In aged mouse models, treatment with these nanoparticles significantly improved spatial learning and memory abilities and exploratory behavior, effectively protecting hippocampal neuronal morphology and reducing neuronal damage.
[0009] In some embodiments, the mass ratio of monoselenomeric curcumin to DSEP-PEG is (5-10):(1-5).
[0010] In some implementations, the molecular weight of PEG is 200-4000.
[0011] In some implementations, DSEP-PEG is DSEP-PEG2000.
[0012] In some embodiments, the raw materials also include DSPE-PEG-Tet1, and the mass ratio of DSEP-PEG to DSPE-PEG-Tet1 is (1-10):(1-5).
[0013] In some implementations, DSPE-PEG-Tet1 is DSPE-PEG2000-Tet1.
[0014] In some embodiments, Tet1 is a short peptide consisting of 12 amino acids with the following amino acid sequence: His-Leu-Asn-Ile-Leu-Ser-Thr-Leu-Trp-Lys-Tyr-Arg.
[0015] This invention utilizes the active targeting properties of Tet1 peptide to neurons. By adding DSPE-PEG-Tet1, monoselenomeric curcumin and neuron-targeting peptide Tet1 are integrated into a single structure. The resulting nanoparticles can simultaneously respond to reactive oxygen species stimulation and actively target neurons, thus solving the technical problem of the lack of intelligent responsiveness and active targeting of nanoparticles in the treatment of neurological diseases.
[0016] According to a second aspect of the present invention, a method for preparing targeted nanoparticles containing monoselenomeric curcumin is provided, comprising the following steps: S1. Dissolve chloropropionic acid in water to obtain a chloropropionic acid solution, then adjust the pH of the chloropropionic acid solution to 9-11 to obtain a first mixed solution; dissolve selenium powder in water under a nitrogen atmosphere, then add an aqueous solution of sodium borohydride to obtain a second mixed solution; add the first mixed solution to the second mixed solution, react for 12-24 h, filter, purify, and obtain selenium dipropionate ether. S2. Selenium dipropionate ether, curcumin and 4-pyrrolidinylpyridine are dissolved in an organic solvent to obtain a reaction system. The reaction system is reacted for 10-15 min under a nitrogen atmosphere and an ice bath. Then, an organic solvent containing 1-ethyl-(3-dimethylaminopropyl)carbodiimide is added to the reaction system and the reaction is carried out for 4-7 h. After washing, diethyl ether is added to the organic phase for precipitation. The solid is filtered and lyophilized to obtain monoselenomeric curcumin. S3. Add monoselenomeric curcumin to a solution containing DSEP-PEG, stir at 600-900 r / min, centrifuge, and freeze-dry to obtain the product. This invention first prepares selenium dipropionate ether, then prepares monoselenomeric curcumin by esterification reaction of selenium dipropionate ether with curcumin, and finally prepares monoselenomeric curcumin into targeted nanoparticles.
[0017] In some embodiments, the organic solvent is dichloromethane.
[0018] In some embodiments, the molar ratio of chloropropionic acid, selenium powder and sodium borohydride is (4-5):(1-2):(1-2).
[0019] In some embodiments, the molar ratio of selenyl dipropionate, curcumin and 4-pyrrolidinylpyridine is (10-100):(10-100):(1-50).
[0020] In some embodiments, in step S1, the purification method is to adjust the pH of the filtrate to 3-4 with dilute hydrochloric acid with a concentration of 6 mol / L, then extract with ethyl acetate, separate the liquid and rotary evaporate the organic layer.
[0021] In some embodiments, in step S1, the pH of the chloropropionic acid solution is adjusted to 9-11 using a 5 mol / L Na2CO3 solution.
[0022] According to a third aspect of the present invention, the use of targeted nanoparticles containing monoselenomeric curcumin in the preparation of medicaments for treating neurocognitive disorders is provided.
[0023] The targeted nanoparticles containing monoselenomeric curcumin of this invention are a nanoplatform that integrates reactive oxygen species-responsive drug release, neuronal targeted delivery, and multiple pharmacological activities of curcumin (antioxidant and anti-inflammatory). It can efficiently penetrate the blood-brain barrier, actively target neurons, and intelligently release drugs in the pathological microenvironment. By synergistically regulating the two core pathological processes of neurocognitive dysfunction, namely oxidative stress and neuroinflammation, it can more effectively protect neurons, improve cognitive function, and thus treat neurocognitive dysfunction.
[0024] In some implementations, neurocognitive impairment includes Alzheimer's disease and vascular dementia.
[0025] The beneficial effects of this invention are as follows: (1) The present invention uses monoselenomeric curcumin as raw material. Monoselenomeric curcumin has high chemical stability and high responsiveness to reactive oxygen species. It can rapidly release curcumin in a pathological reactive oxygen species environment, thereby solving the technical problem in the prior art that curcumin is difficult to effectively penetrate the blood-brain barrier and the effective drug concentration in brain lesions is insufficient.
[0026] (2) The targeted nanoparticles containing monoselenopolymer curcumin of the present invention integrate reactive oxygen species-responsive drug release with multiple pharmacological activities of curcumin (antioxidant, anti-inflammatory), which can efficiently cross the blood-brain barrier and be precisely delivered to diseased neurons.
[0027] (3) The present invention also introduces Tet1 peptide, which has a high efficiency in recognizing neurons, so that the targeted nanoparticles containing monoselenopolymer curcumin can integrate reactive oxygen species responsive drug release, neuronal targeted delivery and multiple pharmacological activities of curcumin. It can actively target neurons, specifically respond to the pathological microenvironment in the brain and intelligently release drugs, avoiding uncontrollable drug release, limited accumulation at the lesion site and causing systemic side effects.
[0028] (4) This invention addresses the core issues in the treatment of neurocognitive dysfunction, such as drug delivery barriers, poor lesion targeting, and complex pathological mechanisms that make synergistic intervention difficult. It provides a novel nanomedicine delivery system solution that integrates intelligent response, efficient targeting, and multiple therapeutic functions. The targeted nanoparticles containing monoselenopolymer curcumin synergistically combat oxidative stress and neuroinflammation, and can synergistically regulate the two core pathological mechanisms of the vicious cycle of oxidative stress and neuroinflammation, thereby treating neurocognitive dysfunction. Attached Figure Description
[0029] Figure 1 The image shows the proton NMR spectrum of curcumin containing monoselenobonds; Figure 2 Fourier transform infrared spectra of curcumin, selenium dipropionate ether, and monoselenocuric acid containing monoselenobonds; Figure 3 The UV-Vis absorption spectra of DSPE-PEG-Tet1, Poly(Cur-co-Se) NPs, and Poly(Cur-co-Se)@Tet1 NPs are shown. Figure 4 Particle size distribution of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs; Figure 5 Zeta potential plots for Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs; Figure 6 Storage stability and polydispersity index of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs stored at 4°C for 1-7 days; Figure 7 (A) is a transmission electron microscope image of Poly(Cur-co-Se) NPs. Figure 7 (B) is a transmission electron microscope image of Poly(Cur-co-Se)@Tet1 NPs; Figure 8 The hemolysis rates of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs at different concentrations; Figure 9 The cumulative curcumin release curves of Poly(Cur-co-Se)@Tet1 NPs in different release media; Figure 10 Cell viability of cells treated with different concentrations of H2O2; Figure 11 Cell survival rates in H2O2-induced oxidative stress models treated with different concentrations of curcumin and Poly(Cur-co-Se)@Tet1 NPs; Figure 12 ROS levels in cells of each H2O2-induced oxidative stress model group; Figure 13Time-dependent in vivo fluorescence imaging of Poly(Cur-co-Se)@Tet1 NPs and Poly(Cur-co-Se) NPs in mice after intravenous injection; Figure 14 Organ fluorescence images of Poly(Cur-co-Se)@Tet1 NPs and Poly(Cur-co-Se) NPs. Detailed Implementation
[0030] The present invention will now be described in further detail with reference to the accompanying drawings, but the embodiments of the present invention are not limited thereto. The raw materials and reagents involved in the following embodiments are all commercially available.
[0031] The DSEP-PEG in this embodiment of the invention is 1,2-distearyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol 2000 (DSPE-PEG2000), catalog number: 80010201-2000-1g, purchased from Carbon Technology.
[0032] DSEP-PEG-Tet1 is DSEP-PEG2000-Tet1, purchased from Jier Biochemical (Shanghai) Co., Ltd.
[0033] It should be noted that DSEP-PEG2000 is only one embodiment of this application, and nanoparticles can also be constructed from DSPE-PEG with other PEG molecular weights (such as PEG200, PEG400, PEG4000).
[0034] Example 1 This embodiment provides a targeted nanoparticle (Poly(Cur-co-Se) NPs) containing monoselenopolymer, which is prepared by the following steps: (1) Synthesis of selenium dipropionate ether (SeDPA) Weigh 4.3 g of chloropropionic acid into a glass bottle, add 20 mL of deionized water to dissolve it, and adjust the pH to 9-11 with saturated Na2CO3 to obtain a chloropropionic acid solution for later use. Weigh 1.6 g of selenium powder into a reaction flask, add 20 mL of deionized water, and stir gently under nitrogen protection. Weigh 1.6 g of sodium borohydride, dissolve it in 10 mL of deionized water to prepare an aqueous solution, and add it to the reaction flask. After the solution becomes clear, add the prepared chloropropionic acid solution dropwise to the reaction flask and react at room temperature for 24 h. After the reaction is complete, filter the reaction solution, adjust the pH of the filtrate to 3-4 with dilute hydrochloric acid, extract twice with 40 mL of ethyl acetate, separate the layers, and rotary evaporate the organic layer to obtain 2.1 g of white solid.
[0035] (2) Synthesis of curcumin containing monoselenobonds 40 mg of selenium dipropionate ether, 65 mg of curcumin, and 105 mg of 4-pyrrolidinopyridine were dissolved in 10 mL of dichloromethane (DCM) and reacted in an ice bath under nitrogen protection for 10 min. 85 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) was dissolved in 5 mL of dichloromethane (DCM) and added dropwise to the reaction system. The reaction was carried out at room temperature for 6 h. The mixture was washed three times with acid water (0.1 mol / L hydrochloric acid aqueous solution), precipitated with diethyl ether (20 times the volume of dichloromethane), dried under vacuum, and lyophilized to obtain poly(Cur-co-Se) containing monoselenobonds.
[0036] (3) Synthesis of Poly(Cur-co-Se) NPs Add 4 mg of Poly(Cur-co-Se) to deionized water containing 2 mg of DSEP-PEG, stir at 800 r / min for 2 hours, centrifuge at 5000 rpm, and then freeze-dry at -20℃ to obtain the product.
[0037] Example 2 This embodiment provides a targeted nanoparticle (Poly(Cur-co-Se)@Tet1NPs) containing monoselenopolymer curcumin, which is prepared by the following steps: (1) Synthesis of selenium dipropionate ether Weigh 4.3 g of chloropropionic acid into a glass bottle, add 20 mL of deionized water to dissolve it, and adjust the pH to 9-11 with saturated Na2CO3. Weigh 1.6 g of selenium powder into a reaction flask, add 20 mL of deionized water, and stir gently under nitrogen protection. Weigh 1.6 g of sodium borohydride, dissolve it in 10 mL of deionized water to prepare an aqueous solution, and add it to the reaction flask. After the solution becomes clear, add the prepared chloropropionic acid solution dropwise to the reaction flask and react at room temperature for 24 h. After the reaction is complete, filter the reaction solution, adjust the pH of the filtrate to 3-4 with dilute hydrochloric acid, extract twice with 40 mL of ethyl acetate, separate the layers, and rotary evaporate the organic layer to obtain 2.1 g of white solid.
[0038] (2) Synthesis of curcumin containing monoselenobonds 40 mg of selenium dipropionate ether, 65 mg of curcumin, and 105 mg of 4-pyrrolidinopyridine were dissolved in 10 mL of dichloromethane (DCM) and reacted in an ice bath under nitrogen protection for 10 min. 85 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) was dissolved in 5 mL of dichloromethane (DCM) and added dropwise to the reaction system. The reaction was carried out at room temperature for 6 h. The mixture was washed three times with acid water (0.1 mol / L hydrochloric acid aqueous solution), precipitated with diethyl ether (20 times the volume of dichloromethane), dried under vacuum, and lyophilized to obtain poly(Cur-co-Se) containing monoselenobonds.
[0039] (3) Synthesis of Poly(Cur-co-Se)@Tet1 NPs Add 4 mg of Poly(Cur-co-Se) to deionized water containing 1.5 mg of DSEP-PEG and 0.5 mg of DSPE-PEG-Tet1, stir at 800 r / min for 2 hours, centrifuge at 5000 rpm, and then freeze-dry at -20℃ to obtain the product.
[0040] 1. Structural verification of targeted nanoparticles containing monoselenomeric curcumin 1.1 Proton NMR spectrum (NMR) 1 H NMR) The monoselenopolymer (Poly(Cur-co-Se)) prepared in the examples was subjected to... 1 ¹H NMR characterization, using tetramethylsilane TMS as a reference, yielded the following results: Figure 1 As shown. By Figure 1 It can be seen that the multiple peaks of Poly(Cur-co-Se) in the aromatic region (6.8-7.5 ppm) correspond to the hydrogens on the benzene ring of curcumin (g, f, e, d, h); the peak (i) at 6.0-6.5 ppm corresponds to the unsaturated double bond hydrogen of curcumin; and the strong peak (c) at 3.8-4.0 ppm corresponds to the methoxy hydrogen (-OCH3) on the benzene ring. The peaks (a, b) in the 2.5-3.5 ppm region belong to the methylene hydrogen (-CH2-Se-CH2-) attached to the selenium atom in the SeDPA unit. The simultaneous appearance of characteristic hydrogen signals of curcumin and SeDPA in the spectrum, and the absence of obvious free monomer peaks, prove that curcumin and SeDPA have successfully copolymerized to form the target polymer. Figure 1 The strong peak at 2.5 ppm represents the signal of residual water in the solvent DMSO.
[0041] 1.2 Fourier Transform Infrared Spectroscopy (FTIR) Fourier transform infrared spectroscopy was performed on curcumin (Cur), SeDPA, and Poly(Cur-co-Se), and the results are as follows: Figure 2 As shown in the infrared spectrum, the three curves (Cur, SeDPA, and Poly(Cur-co-Se)) exhibit characteristic absorption differences in different wavenumber ranges, with key variations concentrated in the 1700-1760 cm⁻¹ range. -1 Region. SeDPA at 1700 cm -1 A distinct absorption peak appears at [value missing], corresponding to the stretching vibration of C=O in its molecule; while the C=O absorption peak of the polymer Poly(Cur-co-Se) (blue curve) shows a significant blue shift to 1760 cm⁻¹. -1 The peak shape is also sharper. This blue shift indicates that the hydroxyl group of curcumin underwent an esterification reaction with the carboxyl group of SeDPA, forming an ester bond, which altered the chemical environment of C=O, leading to an increase in its stretching vibration frequency. Simultaneously, curcumin at 3500 cm⁻¹... -1 The broad peaks near the polymer (corresponding to the stretching of the phenolic hydroxyl group OH) are significantly weakened in the polymer product, further confirming the participation of the hydroxyl group in the reaction. The shift of the C=O absorption peak and the change of the OH peak in the infrared spectrum directly prove that curcumin and SeDPA have successfully polymerized through esterification to generate the target copolymer Poly(Cur-co-Se).
[0042] 1.3 Ultraviolet Spectrophotometer The optical absorption properties of DSPE-PEG-Tet1, Poly(Cur-co-Se) NPs, and Poly(Cur-co-Se)@Tet1 NPs were characterized using UV-Vis absorption spectroscopy. The test wavelength range was 200–800 nm. The results are as follows: Figure 3As shown. DSPE-PEG-Tet1 (green curve) exhibits a strong absorption peak only in the short-wavelength ultraviolet region around 200 nm (absorbance peak close to 3.0 au), and the absorbance rapidly decreases to the baseline with increasing wavelength, reflecting the inherent optical characteristics of Tet1—significant absorption only in short-wavelength ultraviolet light; Poly(Cur-co-Se) NPs (orange curve) show an absorption signal in the 200 nm ultraviolet region, and simultaneously show a characteristic absorption peak in the visible light region around 400 nm (absorbance peak approximately 0.5 au). This peak corresponds to the electronic transition of the curcumin conjugated π system in Poly(Cur-co-Se) NPs, which is a hallmark signal of its active structure; the absorption spectrum of Poly(Cur-co-Se)@Tet1 NPs (blue curve) retains both the strong absorption characteristics of Tet1 in the 200 nm ultraviolet region and the characteristic absorption peak of Poly(Cur-co-Se) NPs around 400 nm; compared with Poly(Cur-co-Se)... Compared to NPs, its absorption peak in the 400nm region is wider and its peak absorbance is increased to 1.0 au.
[0043] 2. Physicochemical characterization of polycurcumin nanoparticles 2.1 Particle size distribution and Zate potential The particle size distribution and zeta potential of Poly(Cur-co-Se) NPs prepared in Example 1 and Poly(Cur-co-Se)@Tet1 NPs prepared in Example 2 were characterized by dynamic light scattering (DLS; Malver, United Kingdom). The prepared nanoparticles were diluted with deionized water to a concentration of approximately 0.05% (w / v) and then measured using DLS. The results are as follows. Figure 4 and Figure 5 As shown. From Figure 4 It can be seen that the particle size distributions of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs both exhibit a single-peak characteristic, with peak particle sizes concentrated at 64.120±1.000 nm and 72.730±0.312 nm, respectively; the absence of multi-peak or broad-peak distribution indicates good size uniformity and excellent dispersibility of the nanoparticles. Figure 5 It can be seen that the Zeta potentials of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs are approximately -21.033±3.694 mV and -16.533±0.635 mV, respectively, exhibiting negative potential characteristics, and the absolute values of the potentials are both greater than 15 mV.
[0044] 2.2 Stability of Nanoparticles Dynamic light scattering (DLS) was used to characterize the changes in particle size and polydispersity index (PDI) of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs after 7 days of storage at 4 °C, in order to assess their long-term storage stability. The results are as follows: Figure 6 As shown. By Figure 6 It can be seen that the particle size of Poly(Cur-co-Se) NPs remained around 60 nm during the 7-day storage period, and the particle size of Poly(Cur-co-Se)@Tet1 NPs remained around 70 nm during the 7-day storage period. Both maintained a PDI of around 0.20, remaining at a consistently low level (PDI < 0.3 usually indicates good particle dispersion uniformity), with no significant increase within 7 days. After 7 days of storage at 4℃, the particle size of the targeted nanoparticles containing monoselenocuric acid did not increase significantly, and the PDI remained at a low level, demonstrating excellent long-term storage stability. The PDI remaining around 0.20 indicates that the size uniformity of the nanoparticles was not compromised, and the dispersion was stable.
[0045] 2.3 Morphology Verification of Nanoparticles Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs were characterized by transmission electron microscopy (TEM). TEM images of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs (scale bar: 200 nm) are shown below. Figure 7 As shown. By Figure 7 It can be seen that both Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs exhibit spherical morphology, with clear particle outlines, complete boundaries, and no obvious irregular aggregates. The nanoparticles are uniformly dispersed under a 200 nm field of view, without large-area aggregation, and are mainly distributed as independent single particles.
[0046] 3. Verification of the biosafety and intelligent release of nanoparticles 3.1 Hemolysis test The hemocompatibility of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs was evaluated using an in vitro hemolysis assay, with the hemolysis rate as the evaluation index. A positive control, a negative control, and a treatment group were set up. The positive control group consisted of 5% red blood cell suspension and pure water; the negative control group consisted of 5% red blood cell suspension and physiological saline; and the treatment group consisted of 5% red blood cell suspension and different concentrations of Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs, including six concentration gradients of 25, 50, 100, 200, 400, and 800 μg / mL. The results of the in vitro hemolysis assay (e.g., ...) were recorded. Figure 8 The results showed that Poly(Cur-co-Se) NPs and Poly(Cur-co-Se)@Tet1 NPs exhibited concentration-dependent differences within the concentration range of 25–800, but neither reached a significant level of hemolysis, and there was no significant difference in hemolysis compared to the positive control group. The results of both positive and negative controls were reliable; the hemolysis rate in the positive control was close to 100%, and the negative control showed no hemolysis, indicating that the experimental system was free of exogenous contamination and the operation was performed correctly. This demonstrates that the material has good hemolytic safety at the experimental concentrations.
[0047] 3.2 Drug release experiment Curcumin exhibits a characteristic absorption peak in the visible light region, and within a certain concentration range, its absorbance shows a good linear relationship with concentration. By measuring the absorbance of standard solutions of curcumin at different concentrations at the characteristic absorption wavelength, a standard curve was plotted and a regression equation was fitted. This equation was then used to calculate the drug concentration of nanoparticles in the release medium, thereby obtaining the cumulative release rate.
[0048] The cumulative release rate of Poly(Cur-co-Se)@Tet1 NPs in different media was verified using a drug release experiment. An appropriate amount of curcumin standard was taken, and a trace amount of anhydrous ethanol was added. The solution was ultrasonically vibrated until completely dissolved to prepare a curcumin ethanol stock solution. This stock solution was then slowly added dropwise to the aforementioned PBS solution containing Tween 80 while magnetically stirring until the solution became clear and transparent, preventing curcumin precipitation. Using a gradient dilution method, the clear solution was successively diluted to prepare a series of curcumin standard working solutions of 4, 2, 1, 0.5, and 0.25 μg / mL, which were stored in the dark for later use. Using PBS containing Tween 80 as a blank control, the above series of standard working solutions were placed in a UV spectrophotometer and scanned across the entire wavelength range of 360–470 nm. The absorbance values and corresponding wavelengths were recorded, and the characteristic absorption peak wavelength of curcumin was determined to be 426 nm. Plot a standard curve, fit it using linear regression to obtain the regression equation A = aC + b (where a is the slope and b is the intercept), and calculate the correlation coefficient R. 2 Requires R2 ≥0.99, ensuring good linearity. Equal amounts of Poly(Cur-co-Se)@Tet1 NPs lyophilized powder were placed in separate dialysis bags, dissolved in 10 mL of release medium, and both ends of the dialysis bags were sealed. The dialysis bags were then immersed in a conical flask containing 50 mL of release medium and placed in a constant-temperature shaker at 37℃ and 100 r / min for release. At preset time points (e.g., 5, 10, 15, 20, 25, 50, 100 h), 1 mL of release medium was aspirated, and an equal volume of fresh release medium at the same temperature was added to maintain a constant volume of the release system. The aspirated release medium was placed in a UV spectrophotometer, and the absorbance value was measured at a wavelength of 426 nm. The corresponding curcumin concentration was calculated by substituting the values into the standard curve regression equation. The results are as follows: Figure 9 As shown.
[0049] from Figure 9 It can be seen that in a simulated oxidative stress microenvironment, the curcumin release rate of Poly(Cur-co-Se)@Tet1 NPs is significantly higher than that in a normal physiological environment, indicating that the nanoparticles possess oxidative stress-responsive release characteristics. This characteristic allows curcumin to be preferentially released at the lesion site, improving drug targeting. This release characteristic enables Poly(Cur-co-Se)@Tet1 NPs to precisely release curcumin in the oxidative stress region of the brain, improving drug utilization efficiency and reducing drug exposure in normal tissues, providing an advantage in dosage form design for its clinical application.
[0050] Through the above experiments, this invention details the entire process of developing monoseleno-bonded curcumin-targeted nanoparticles, from polymer (containing monoseleno-bonded curcumin) synthesis, nanoparticle preparation, targeted modification, to preliminary physicochemical properties, biosafety, and intelligent release behavior verification. This implementation scheme demonstrates the successful construction of a neuronal-targeting nanocarrier system with a well-defined structure, uniform particle size, good stability, high biocompatibility, and reactive oxygen species-responsive drug release capability, laying a solid material foundation for subsequent functional verification at the cellular and animal levels.
[0051] 4. Validation of the in vitro antioxidant stress resistance of targeted nanoparticles containing monoselenomeric curcumin 4.1 Establishment of a cellular oxidative stress model and screening of nanoparticle safety and optimal concentration The mouse hippocampal neuronal cell line HT22 was used as an in vitro model. Cells were routinely cultured in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin in a constant temperature incubator at 37°C and 5% CO2.
[0052] To establish an oxidative stress model, the optimal concentration and duration of hydrogen peroxide (H2O2) exposure must first be determined. HT22 cells were cultured at approximately 5 × 10⁶ cells per well. 3Cells were seeded at a density of 5 × 10⁶ cells / well in 96-well plates and cultured overnight to allow cell adhesion. A control group (NC, containing only complete medium) and treatment groups with different concentrations of H₂O₂ were set up. For cell culture and seeding, HT22 cells in the logarithmic growth phase were used, digested with 0.25% trypsin, and resuspended in high-glucose DMEM medium containing 10% FBS and 1% penicillin-streptomycin antibiotics. The cell density was adjusted to 5 × 10⁶ cells / well. 3 Cells were seeded per well in a 96-well cell culture plate, with 100 μL of cell suspension added to each well. The plate was incubated at 37°C with 5% CO2 for 24 h until complete cell adhesion. Afterward, the old culture medium was aspirated from the 96-well plate, and the cells were gently washed once with sterile PBS to remove residual serum (to prevent the antioxidants in serum from neutralizing H2O2). The H2O2 stock solution was diluted to six concentration gradients (0, 50, 100, 200, 400, and 800 μmol / L) using serum-free, high-glucose DMEM medium (prepared fresh and handled in the dark). 100 μL of the corresponding concentration of H2O2 working solution was added to each well, with three replicates per group. The plate was returned to the incubator for another 24 h. After H2O2 treatment, the H2O2 working solution was aspirated from each well, and the cells were washed twice with sterile PBS. Add 100 μL of serum-free medium containing 10% CCK-8 reagent to each well and incubate in the dark for 2 h. Measure the absorbance (OD value) of each well at 450 nm using a microplate reader and record the experimental data. Cell viability was assessed using the CCK-8 assay. By plotting the cell viability as a function of H2O2 concentration and time, an H2O2 concentration that induces approximately 50% cell death was selected as the modeling condition for subsequent experiments. The results are shown below. Figure 10 As shown, the final H2O2 concentration selected for modeling was 200 μmol / L.
[0053] After determining the modeling conditions, an oxidative stress model was established to evaluate the safety of curcumin (Cur) and the targeted nanoparticles (Poly(Cur-co-Se)@Tet1 NPs) containing monoselenopolymer curcumin from Example 2 on normal HT22 cells. To clarify the protective effects of Cur and Poly(Cur-co-Se)@Tet1 NPs against H2O2-induced cellular oxidative stress damage, this experiment included a normal control group (NC), an oxidative stress model group (Model), and four curcumin pretreatment groups (0.5, 1, 2, and 4 μmol / L). Changes in cell viability were detected and bar charts were plotted. Using cell viability as the observation indicator, the H2O2 model group showed significantly reduced cell viability compared to the normal control group, indicating successful replication of the oxidative stress damage model.
[0054] Cells were co-incubated with 200 μmol / L H2O2 and different concentrations of curcumin or targeted nanoparticles containing monoseleno-bonded curcumin (0.5, 1, 2, 4 μmol / L, based on curcumin equivalents) for 24 hours. Cell viability was detected by the CCK-8 assay to ensure that the formulation itself had no significant cytotoxicity (viability >90%) within the concentration range of subsequent experiments. The results are as follows: Figure 11 As shown.
[0055] The CCK-8 assay is performed as follows: 10 μL of CCK-8 solution is added to each well, and the cells are incubated for 3 hours. Then, the absorbance (A) of each well is measured at 450 nm using a microplate reader. Cell viability (%) = (A treatment group - A blank group) / (A control group - A blank group) × 100%.
[0056] from Figure 11 It can be seen that at concentrations of 0.5, 1, and 2 μmol / L, the cell viability of the Poly(Cur-co-Se)@Tet1 NPs group was significantly higher than that of the Cur group at the same concentration. Furthermore, the increase in cell viability was more pronounced with increasing drug concentration, indicating that this nano-formulation can more effectively improve H2O2-induced cell damage and exert a stronger protective effect. At a concentration of 4 μmol / L, there was still a statistically significant difference in cell viability between the two groups, but the overall viability was at a low level, suggesting that excessively high concentrations may have some toxicity to cells, thus weakening the protective effect.
[0057] Next, we verified the in vitro antioxidant stress resistance of targeted nanoparticles containing monoseleno-bonded curcumin by setting up NC group, Model group, Cur group, Poly(Cur-co-Se) NPs group and Poly(Cur-co-Se)@Tet1 NPs group. HT22 cells were incubated in the NC group for 24 h; HT22 cells in the Model group were co-incubated with 200 μmol / L H2O2 for 24 h; HT22 cells in the Cur group were co-incubated with 200 μmol / L H2O2 and 1 μmol / L Cur for 24 h; HT22 cells in the Poly(Cur-co-Se) NPs group were co-incubated with 200 μmol / L H2O2 and 1 μmol / L Poly(Cur-co-Se) NPs for 24 h; and HT22 cells in the Poly(Cur-co-Se)@Tet1 NPs group were co-incubated with 200 μmol / L H2O2 and 1 μmol / L Poly(Cur-co-Se)@Tet1 NPs for 24 h. The ROS levels in HT22 cells were then detected by flow cytometry, and the results are as follows: Figure 12 As shown. From Figure 12As can be seen, compared with the NC group, the relative ROS level in the Model group was significantly increased, indicating that H2O2 successfully induced the cells to produce excess ROS, and the oxidative stress model was effectively constructed. Compared with the Model group, the relative ROS levels in the Cur group, Poly(Cur-co-Se) NPs group, and Poly(Cur-co-Se)@Tet1 NPs group all showed a decreasing trend. Among them, the Poly(Cur-co-Se)@Tet1 NPs group could significantly reduce the ROS level (P<0.05), suggesting that Cur and its nano-formulation can scavenge excess ROS to varying degrees and exert antioxidant effects. Intergroup comparisons showed no statistically significant differences between the Cur group and the Poly(Cur-co-Se) NPs group, nor between the Poly(Cur-co-Se)@Tet1 NPs group, and also no significant differences between the Poly(Cur-co-Se) NPs group and the Poly(Cur-co-Se)@Tet1 NPs group. However, the Poly(Cur-co-Se)@Tet1 NPs group showed the most significant effect in reducing ROS levels. Meanwhile, there were no significant differences between the NC group and the Cur group, the Poly(Cur-co-Se) NPs group, or the Poly(Cur-co-Se)@Tet1 NPs group. This suggests that while the three intervention methods improve oxidative stress and clear excess ROS, they do not interfere with the ROS levels of normal cells and have no significant impact on normal physiological states, demonstrating good biocompatibility.
[0058] 5. Validation of the in vivo targeting ability of targeted nanoparticles containing monoselenomeric curcumin 5.1 Biodistribution and Brain Targeting of Nanoparticles in Aged Mice Mice with a brain cognitive impairment model established through carotid artery exposure were used as the research subjects. Mice were randomly divided into two groups of 3-5 mice each: a Poly(Cur-co-Se) NPs group and a Poly(Cur-co-Se)@Tet1 NPs group. For in vivo imaging, fluorescently labeled nanoparticles with the probe CY5.5 were used. Mice in each group were administered the corresponding fluorescently labeled nanoparticles or an equal volume of saline via tail vein injection at a dose of 20 mg / kg (based on nanoparticles). At multiple time points after injection (0 h, 4 h, 8 h, 12 h, 16 h, 20 h, 24 h), mice were appropriately anesthetized with inhaled anesthetics such as isoflurane, and then placed in the imaging chamber of a small animal in vivo three-dimensional fluorescence imaging system. Excitation / emission filters were adjusted to the wavelength corresponding to the dye, and fluorescence images of the entire mouse body (especially the head region) were acquired. The fluorescence signal intensity in the mouse head region at different time points was quantitatively analyzed using system software, and fluorescence intensity-time curves were plotted to compare the accumulation dynamics of targeted and non-targeted nanoparticles in the brain. This study investigated the time-dependent distribution and organ targeting of Poly(Cur-co-Se)@Tet1 NPs and Poly(Cur-co-Se) NPs in mice after intravenous (IV) administration using in vivo fluorescence imaging. The time-dependent in vivo fluorescence imaging of Poly(Cur-co-Se)@Tet1 NPs and Poly(Cur-co-Se) NPs in mice after IV administration is shown in the figure below. Figure 13 As shown. From Figure 13In vivo imaging results showed that both the Poly(Cur-co-Se)@Tet1NPs group and the Poly(Cur-co-Se) NPs group exhibited a "linear increase followed by stabilization," with highly synchronized change patterns. The overall trend of the Poly(Cur-co-Se)@Tet1 NPs group was a continuous increase from 25.008 at 0 h, reaching a peak of 26.468 at 20 h, followed by a slight decrease to 26.466 at 24 h, exhibiting a "continuous increase to peak and then stabilization" characteristic. In terms of the magnitude of increase, the Poly(Cur-co-Se)@Tet1NPs group increased by an average of 1.460 from 0 to 20 h, an increase of approximately 5.8%, and remained relatively stable from 20 to 24 h without a significant decrease, suggesting that this material has a long signal response duration and strong stability. The overall trend of the Poly(Cur-co-Se) NPs group was highly synchronized with that of the Poly(Cur-co-Se)@Tet1 NPs group, rising from 24.181 at 0h to a peak of 25.445 at 8h, and then slowly declining to 25.257 at 24h, exhibiting a "rapid rise followed by slow stabilization" characteristic. In terms of the growth rate, the Poly(Cur-co-Se) NPs group increased by an average of 1.264 (25.445-24.181) from 0-8h, an increase of approximately 5.2%, and then slightly decreased from 8-24h (a decrease of 0.188), suggesting that the signal response peak of this material appeared earlier, but its later stability was slightly weaker than that of the Poly(Cur-co-Se)@Tet1 NPs group. Secondly, the signal value of the Poly(Cur-co-Se)@Tet1 NPs group was higher than that of the Poly(Cur-co-Se) NPs group throughout the entire process, and the difference was stable and practically significant. Fluorescence intensity (In-RLU) quantification curves further validated this trend. The Ir RLU value of Poly(Cur-co-Se)@Tet1 NPs increased significantly over time and was consistently higher than that of the Poly(Cur-co-Se) NPs group. The results indicate that Tet-1 modification can enhance the cyclic stability or targeted accumulation ability of nanoparticles in vivo, leading to continuous accumulation of fluorescence signals over time. Twenty-four hours after injection, mice were euthanized, and major organs such as the heart, liver, spleen, lungs, kidneys, and whole brain were rapidly dissected and removed. Fluorescence images of each organ were obtained, and the results are as follows: Figure 14 As shown, from Figure 14 It can be seen that, compared to Poly(Cur-co-Se) NPs, Poly(Cur-co-Se)@Tet1 NPs are more concentrated throughout the brain, indicating that Poly(Cur-co-Se)@Tet1 NPs achieve active targeting of neurons by modifying neuron-targeting peptides. By combining the Tet-1 peptide with reactive oxygen species-responsive nanocarriers, a three-level delivery system of "barrier crossing-neuron recognition-response release" was successfully constructed.
[0059] This invention provides a method for preparing targeted nanoparticles of polycurcumin containing monoselenobonds. The method first synthesizes a polycurcumin polymer containing monoselenobonds with reactive oxygen species responsiveness via esterification, and verifies its structure using 1H NMR and IR spectroscopy. Subsequently, the polymer is self-assembled into nanoparticles via nanoprecipitation, and their particle size, potential, morphology, and stability are systematically characterized. Finally, neuron-targeting peptides are modified onto the surface of the nanoparticles, and the successful modification is verified by UV spectroscopy, thereby obtaining nanoparticles with neuron-targeting function.
[0060] Next, the antioxidant stress capacity of the nanoparticles in an in vitro model was verified. Using mouse hippocampal neurons as a model, oxidative stress conditions were established, and the biosafety, optimal concentration, and ability to scavenge intracellular reactive oxygen species of free curcumin, untargeted nanoparticles, and targeted nanoparticles were systematically evaluated to clarify the role of targeted nanoparticles in enhancing antioxidant protection at the cellular level.
[0061] To verify the targeting and neuroprotective effects of the nanoparticles in vivo, aged mice were used as a model. The distribution of the nanoparticles in vivo was dynamically observed using in vivo imaging technology, especially their accumulation in the brain and hippocampus. This confirmed their ability to cross the blood-brain barrier and target neurons, and comprehensively verified their in vivo therapeutic efficacy.
[0062] The above descriptions are merely some embodiments of the present invention. Those skilled in the art can make various modifications and improvements without departing from the inventive concept of the present invention, and these all fall within the scope of protection of the present invention.
Claims
1. Targeted nanoparticles containing monoselenomeric curcumin, characterized in that, Its raw materials are mainly composed of monoselenomeric curcumin and DSEP-PEG; The structural formula of curcumin containing a single selenium bond is: Equation (I), In equation (I), n is 2-100.
2. The targeted nanoparticles containing monoselenomeric curcumin according to claim 1, characterized in that, The mass ratio of monoselenomeric curcumin to DSEP-PEG is (5-10):(1-5).
3. The targeted nanoparticles containing monoselenomeric curcumin according to claim 1 or 2, characterized in that, The raw materials also include DSPE-PEG-Tet1, with a mass ratio of DSEP-PEG to DSPE-PEG-Tet1 of (1-10):(1-5); Tet1 is a short peptide composed of 12 amino acids, with the amino acid sequence His-Leu-Asn-Ile-Leu-Ser-Thr-Leu-Trp-Lys-Tyr-Arg.
4. The method for preparing targeted nanoparticles containing monoselenomeric curcumin according to any one of claims 1-3, characterized in that, Includes the following steps: S1. Dissolve chloropropionic acid in water to obtain a chloropropionic acid solution, then adjust the pH of the chloropropionic acid solution to 9-11 to obtain a first mixed solution; dissolve selenium powder in water under a nitrogen atmosphere, then add an aqueous solution of sodium borohydride to obtain a second mixed solution; add the first mixed solution to the second mixed solution, react for 12-24 h, filter, adjust the pH of the filtrate to 3-4, purify, and obtain selenium dipropionate ether; S2. Selenium dipropionate ether, curcumin and 4-pyrrolidinylpyridine are dissolved in an organic solvent to obtain a reaction system. The reaction system is reacted for 10-15 min under a nitrogen atmosphere and an ice bath. Then, an organic solvent containing 1-ethyl-(3-dimethylaminopropyl)carbodiimide is added to the reaction system and the reaction is carried out for 4-7 h. After washing, diethyl ether is added to the organic phase for precipitation. The solid is filtered and lyophilized to obtain monoselenomeric curcumin. S3. Add monoselenomeric curcumin to a solution containing DSEP-PEG, stir at 600-900 r / min, centrifuge, and freeze-dry to obtain the product.
5. The preparation method according to claim 4, characterized in that, The molar ratio of chloropropionic acid, selenium powder and sodium borohydride is (4-5):(1-2):(1-2).
6. The preparation method according to claim 4, characterized in that, The molar ratio of the dipropionate selenide, curcumin and 4-pyrrolidinylpyridine is (10-100):(10-100):(1-50).
7. The preparation method according to claim 4, characterized in that, The organic solvent is dichloromethane.
8. The preparation method according to claim 4, characterized in that, In step S1, the purification method is to adjust the pH of the filtrate to 3-4 with dilute hydrochloric acid with a concentration of 6 mol / L, then extract with ethyl acetate, separate the liquid and rotary evaporate the organic layer.
9. The use of the targeted nanoparticles containing monoselenomeric curcumin as described in any one of claims 1-3 in the preparation of drugs for treating neurocognitive dysfunction.
10. The application according to claim 9, characterized in that, Neurocognitive impairments include Alzheimer's disease and vascular dementia.
